SCHEMBL25326196

SCHEMBL25326196

O=C(N1CC2(CC(c3nnc(C4CC4)[nH]3)C2)C1)N1CC2(C1)CN(S(=O)(=O)c1ccc(F)cc1F)C2

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ AKR1C3 P42330 2/20 0.39
▸ SPR P35270 2/20 0.36
▸ PKM P14618 2/20 0.34
▸ ALDH1A1 P00352 2/20 0.33
▸ PKLR P30613 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ USP5 P45974 1/20 0.33
▸ DPP4 P27487 6/20 0.33
▸ DPP7 Q9UHL4 5/20 0.33
▸ HTR2A P28223 1/20 0.32
▸ HTR2C P28335 1/20 0.32
▸ KCNH2 Q12809 4/20 0.32
▸ DPP8 Q6V1X1 2/20 0.32
▸ DPP9 Q86TI2 2/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ CCNT1 O60563 1/20 0.32
▸ CDK9 P50750 1/20 0.32
▸ OXTR P30559 1/20 0.32
▸ AKR1B1 P15121 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25324751 0.91 EPHX2 (0.41) AKR1C3SPRKMT2AOXTRAKR1B1
SCHEMBL25323578 0.89 EPHX2 (0.42) SPRPKMKMT2A
SCHEMBL25325171 0.83 AKR1C3 (0.38) AKR1C3ALDH1A1USP5KMT2A
SCHEMBL25327528 0.81 CACNA1B (0.40) PKM
SCHEMBL25325494 0.80 KMT2A (0.43) AKR1C3ALDH1A1KMT2A
SCHEMBL25327912 0.80 AKR1C3 (0.40) AKR1C3PKMALDH1A1MAPTKMT2A
SCHEMBL25325111 0.80 CTSS (0.38) AKR1C3AKR1B1
SCHEMBL25326395 0.80 CACNA1B (0.35) ALDH1A1KMT2A
SCHEMBL25326091 0.80 ALDH1A1 (0.39) ALDH1A1MAPT
SCHEMBL27154637 0.79 MGLL (0.50) AKR1C3SPRPKMALDH1A1PKLR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250099448-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-03-27 — — US claimed
EP-4469446-A1 NEW HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-12-04 — — EP claimed
WO-2023144160-A1 NEW HETEROCYCLIC COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2023-08-03 — — WO claimed
US-20250099448-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-03-27 — — US disclosed
EP-4469446-A1 NEW HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-12-04 — — EP disclosed
WO-2023144160-A1 NEW HETEROCYCLIC COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2023-08-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250099448-A1 HETEROCYCLIC COMPOUNDS OPRM1, CYP1A1, CYP3A4 AKR1C3 257/4885SPR 1574/4885PKM 2418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback